Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;108:2450-2452
Published online before print November 10, 2003, doi: 10.1161/01.CIR.0000102969.09658.F2
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/20/2450    most recent
01.CIR.0000102969.09658.F2v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamashita, T.
Right arrow Articles by Fu, L.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamashita, T.
Right arrow Articles by Fu, L.-T.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Atrial Fibrillation
Related Collections
Right arrow Anticoagulant mechanisms

(Circulation. 2003;108:2450.)
© 2003 American Heart Association, Inc.


Brief Rapid Communications

Thrombomodulin and Tissue Factor Pathway Inhibitor in Endocardium of Rapidly Paced Rat Atria

Takeshi Yamashita, MD, PhD; Akiko Sekiguchi, PhD; Yu-ki Iwasaki, MD, PhD; Kouichi Sagara, MD; Seiji Hatano, MD, PhD; Hiroyuki Iinuma, MD; Tadanori Aizawa, MD, PhD; Long-Tai Fu, MD, PhD

From The Cardiovascular Institute, Tokyo, Japan.

Correspondence to Takeshi Yamashita, MD, PhD, The Cardiovascular Institute, Roppongi 7-3-10, Minato-ku, Tokyo 106-0032, Japan. E-mail yamt-tky{at}umin.ac.jp

Received June 6, 2003; de novo received August 8, 2003; revision received September 26, 2003; accepted September 26, 2003.

Background— Atrial fibrillation (AF) is well known as one of the cardiogenic causes for thromboembolism. Although decreased flow and hypercoagulable state of the blood in the fibrillating atrium have been emphasized as the underlying mechanisms, endocardial dysfunction in maintaining the local coagulation balance could also contribute to the thrombogenesis in AF.

Methods and Results— The paroxysmal AF model was created by rapid atrial pacing in anesthetized rats. To test the hypothesis that AF induces local coagulation imbalance by disturbing the atrial endocardial function, the gene expression of intrinsic anticoagulant factors, thrombomodulin (TM) and tissue factor pathway inhibitor (TFPI), were determined by means of ribonuclease protection assay, Western blotting, and immunohistochemistry. Rapid atrial pacing for 8 hours significantly decreased TM and TFPI mRNA levels in the left atrium but not in the ventricle, leading to the downregulation of their immunoreactive proteins. Immunohistochemical analysis revealed that TM and TFPI were expressed predominantly in the endocardial cells of the normal atrium, presumably preventing local blood coagulation, and that rapid atrial pacing induced the loss of TM and TFPI expression in the endocardium, leading to deficiency in anticoagulant barriers between the atria and the blood.

Conclusions— Rapid atrial pacing acutely downregulated the gene expression of TM and TFPI in the atrial endocardium, thereby inducing local coagulation imbalance on the internal surface of the atrial cavity. These results would support the validity of supplement of anticoagulant molecules deficient in AF.


Key Words: fibrillation • anticoagulants • endocardium




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Etzion, M. Mor, A. Shalev, S. Dror, O. Etzion, A. Dagan, O. Beharier, A. Moran, and A. Katz
New insights into the atrial electrophysiology of rodents using a novel modality: the miniature-bipolar hook electrode
Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1460 - H1469.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Goette, A. Bukowska, U. Lendeckel, M. Erxleben, M. Hammwohner, D. Strugala, J. Pfeiffenberger, F.-W. Rohl, C. Huth, M. P.A. Ebert, et al.
Angiotensin II Receptor Blockade Reduces Tachycardia-Induced Atrial Adhesion Molecule Expression
Circulation, February 12, 2008; 117(6): 732 - 742.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. T. Issac, H. Dokainish, and N. M. Lakkis
Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation: A Systematic Review of the Published Data
J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2021 - 2028.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
T. Yamashita, A. Sekiguchi, T. Kato, T. Tsuneda, Y.-k. Iwasaki, K. Sagara, H. Iinuma, H. Sawada, and T. Aizawa
Angiotensin type 1 receptor blockade prevents endocardial dysfunction of rapidly paced atria in rats
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2007; 8(3): 127 - 132.
[Abstract] [PDF]


Home page
Circ. Res.Home page
W. C. Aird
Phenotypic Heterogeneity of the Endothelium: II. Representative Vascular Beds
Circ. Res., February 2, 2007; 100(2): 174 - 190.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N. K. Kapur, C. B. Deming, S. Kapur, C. Bian, H. C. Champion, J. K. Donahue, D. A. Kass, and J. J. Rade
Hemodynamic Modulation of Endocardial Thromboresistance
Circulation, January 2, 2007; 115(1): 67 - 75.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Christ and U. Ravens
Do we need new antiarrhythmic compounds in the era of implantable cardiac devices and percutaneous ablation?
Cardiovasc Res, December 1, 2005; 68(3): 341 - 343.
[Full Text] [PDF]